Categories of Preference included for recommendations within NCCN Guidelines

The National Comprehensive Cancer Network® (NCCN®) has instituted Categories of Preference for recommendations within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Initially, Categories of Preference will be published for drugs and biologics recommended within the NCCN Guidelines® for Multiple Myeloma. Additional cancer types are forthcoming.

All recommendations in the NCCN Guidelines are considered appropriate. The Categories of Preference are:

  • Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability
  • Other recommended intervention: Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes
  • Useful in certain circumstances: Other interventions that may be used for selected patient populations (defined with recommendation)

Multiple NCCN Guidelines have historically included preferred and other recommended interventions; Categories of Preference will provide consistency in guidance across Guidelines for shared decision-making.

The goals of the NCCN Categories of Preference are to stratify Guidelines to clarify panel and institutional preference for interventions, to provide guidance to users of Guidelines on which recommendations are considered optimal, and to continue to provide a wide range of recommendations to meet varying clinical circumstances and patient preferences.

Transparency of NCCN Guidelines and Compendia development is central to the philosophy, policies, and procedures of NCCN. NCCN posts the policies and processes for developing and maintaining the NCCN Guidelines. These policies are available to the public on the NCCN website. Identification of newly published research, NCCN Member Institution review, external stakeholder submissions, and panel review occur on an ongoing basis with at least annual review performed for NCCN Guidelines for each disease.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows AI can predict prognosis in triple-negative breast cancer